<table class="infobox infobox-institution">
<tr>
<th class="infobox-header" colspan="2">National Hospital for Neurology and Neurosurgery, Queen Square</th>
</tr>
<tr>
<td class="label">Location</td>
<td>London, England, UK</td>
</tr>
<tr>
<td class="label">Type</td>
<td>Specialist Hospital and Research Center</td>
</tr>
<tr>
<td class="label">Founded</td>
<td>1859</td>
</tr>
<tr>
<td class="label">Website</td>
<td><a href="https://www.uclh.nhs.uk/" target="_blank">https://www.uclh.nhs.uk/</a></td>
</tr>
<tr>
<td class="label">Focus Areas</td>
<td>Alzheimer's Disease, Parkinson's Disease, ALS, Multiple Sclerosis, Epilepsy, Movement Disorders, Dementia</td>
</tr>
<tr>
<td class="label">Affiliation</td>
<td>UCL Queen Square Institute of Neurology</td>
</tr>
</table>
National Hospital for Neurology and Neurosurgery, Queen Square
Introduction
Mermaid diagram (expand to render)
The National Hospital for Neurology and Neurosurgery (NHNN) at Queen Square, London, is one of the world's oldest and most prestigious specialist neurological hospitals. Founded in 1859, the hospital has been at the forefront of neurology and neurosurgery for over 160 years, making fundamental contributions to understanding and treating neurological disorders["@uclh2024"]. As part of University College London Hospitals NHS Foundation Trust, the hospital combines world-class clinical care with cutting-edge research, making it a global destination for patients with complex neurological conditions.
Queen Square represents a unique institution where pioneering basic science discoveries have been translated into clinical breakthroughs that have transformed the lives of millions of patients worldwide. The hospital's rich history, combined with its continued commitment to innovation, ensures that it remains at the cutting edge of neurological research and patient care.
History and Institutional Development
Origins and Foundation (1859-1900)
The National Hospital for the Paralysed was founded in 1859 by Dr. Charles Elam as a small facility dedicated to treating patients with paralysis and neurological conditions. The hospital moved to its current location in Queen Square in 1866, establishing itself as the world's first specialist neurological hospital. In 1911, the hospital merged with the National Hospital for the Relief and Cure of Paralysis and Epilepsy, expanding its mission to include epilepsy research and treatment.
The early years of Queen Square were marked by several landmark discoveries that would shape the field of neurology:
- 1870s: Pioneering work on the structure and function of the nervous system
- 1880s: Early studies on localization of neurological function
- 1890s: First systematic studies of reflex responses and motor control
The Golden Era of Neurology (1900-1950)
The first half of the 20th century represented a golden era for Queen Square, with numerous breakthrough discoveries that established modern neurology:
1913: Sir Henry Head, one of the founding figures of modern neurology, established the department of neurological studies at Queen Square, pioneering the study of sensation and neurological examination techniques.
1920s-1930s: Queen Square researchers made fundamental contributions to understanding movement disorders, including early work on Parkinson's disease and the development of neurosurgical approaches to treating movement disorders.
1940s: During World War II, Queen Square became a center for treating head injuries and developing rehabilitation approaches that would influence modern neurorehabilitation.
Modern Era (1950-Present)
The post-war period saw continued expansion and innovation at Queen Square:
- 1950s-1960s: Development of modern neuroimaging techniques
- 1970s-1980s: Introduction of CT scanning and early MRI technology
- 1990s: Integration with the UCL Queen Square Institute of Neurology[@iop2024]
- 2000s-2020s: Advanced neuroimaging, deep brain stimulation, and molecular therapies
Today, Queen Square operates as part of the UCLH NHS Foundation Trust, maintaining its position as one of the world's premier neurological institutions while continuing to push the boundaries of what is possible in neurological diagnosis and treatment.
Clinical Services and Programs
Cognitive Disorders and Dementia
The hospital provides comprehensive diagnostic and treatment services for cognitive disorders[@rodriguez2023][@schott2023]:
Alzheimer's Disease Program
Queen Square's Alzheimer's disease program offers:
- Comprehensive Diagnostic Assessment: Detailed cognitive testing, neuroimaging, and biomarker evaluation
- Medical Management: Pharmacological treatments and disease monitoring
- Clinical Trials: Access to experimental therapies targeting amyloid and tau
- Caregiver Support: Education and support services for families
- Research Programs: Contributing to understanding disease mechanisms
Other Dementia Types
Queen Square provides specialized care for:
- Frontotemporal Dementia: Comprehensive assessment and management of FTD variants[@mendonca2023]
- Dementia with Lewy Bodies: Expert diagnosis and treatment of DLB[@gordon2024]
- Vascular Dementia: Management of vascular cognitive impairment[@rini2023]
- Young Onset Dementia: Services for patients under 65[@masellis2023]
Movement Disorders
Queen Square is world-renowned for movement disorders, offering comprehensive services for Parkinson's disease and related conditions[@foltynie2023][@lees2023]:
Parkinson's Disease Services
- Movement Disorder Specialists: Expert neurologists with decades of experience
- Deep Brain Stimulation: Full evaluation, surgical programming, and follow-up[@warren2023][@zrinzo2024]
- Medication Optimization: Individualized treatment planning
- Physical Therapy: Specialized exercise and rehabilitation programs
- Clinical Trials: Access to new therapies and treatment approaches
Other Movement Disorders
- Essential Tremor: Medical and surgical management
- Dystonia: Botulinum toxin injections and deep brain stimulation
- Huntington's Disease: Comprehensive care including genetic counseling[@moss2023]
- Tic Disorders: Behavioral and pharmacological management
- Ataxia: Diagnosis and rehabilitation
Motor Neuron Disease / ALS
Queen Square hosts one of the UK's leading ALS centers[@hardiman2023][@mehta2023]:
- Multidisciplinary Care Team: Neurologists, respiratory specialists, physiotherapists, and palliative care
- Respiratory Support: Ventilation assessment and support
- Nutritional Support: Assessment and management of swallowing difficulties
- Clinical Trials: Access to experimental therapies
- Research Programs: Contributing to understanding ALS mechanisms and treatment development
Multiple Sclerosis
The MS center provides comprehensive services[@chao2023][@bjornevik2023]:
- Disease-Modifying Therapies: Access to all available treatments
- Symptom Management: Comprehensive approach to fatigue, spasticity, and other symptoms
- Rehabilitation: Physical and occupational therapy
- Clinical Trials: Novel therapeutic agents and treatment approaches
- Neuroimaging: Advanced MRI monitoring of disease activity
Epilepsy
Queen Square provides specialized epilepsy services[@rowan2023]:
- Diagnostic Evaluation: Video-EEG monitoring and advanced imaging
- Medical Management: Antiseizure medication optimization
- Surgical Evaluation: Pre-surgical assessment for candidates
- Ketogenic Diet: Specialist dietary therapy for refractory epilepsy
Other Neurological Conditions
Queen Square treats a comprehensive range of neurological conditions:
- Myasthenia Gravis: Autoimmune neuromuscular disorders[@london2023]
- Peripheral Neuropathy: Inflammatory and inherited neuropathies
- Headache and Migraine: Specialized headache clinics
- Neuromuscular Disorders: Comprehensive muscle and nerve disease services
Research Programs and Centers
Dementia Research Centre
The Dementia Research Centre at Queen Square conducts cutting-edge research on dementia[@schott2023][@rodriguez2023]:
Research Focus
- Clinical Trials: Testing novel therapeutic agents for Alzheimer's disease and other dementias
- Biomarker Studies: Early detection and disease monitoring markers
- Neuroimaging: Advanced MRI and PET studies of dementia[@rytting2024]
- Genetic Studies: Understanding inherited forms of dementia
- ClinicalPhenotyping: Detailed characterization of different dementia subtypes
Key Research Areas
Early Detection: Identifying biomarkers and clinical indicators of preclinical disease
Disease Progression: Understanding how different dementias advance over time
Treatment Response: Developing biomarkers to monitor treatment effects
Prevention Studies: Lifestyle and pharmacological interventions to prevent dementiaWellcome Trust Centre for Neuroimaging
This world-leading imaging center provides state-of-the-art neuroimaging for research[@rytting2024]:
Imaging Capabilities
- Structural Imaging: High-resolution MRI for anatomy
- Functional Imaging: fMRI for brain activity mapping
- Diffusion Imaging: White matter tractography
- Molecular Imaging: PET for amyloid, tau, and other pathology
- Advanced Techniques: Quantitative imaging and multi-parameter mapping
Research Applications
- Understanding disease mechanisms in vivo
- Developing imaging biomarkers for diagnosis and progression
- Tracking treatment response in clinical trials
- Exploring functional connectivity changes in disease
UCL Queen Square Institute of Neurology
The UCL Queen Square Institute of Neurology (ION) represents a partnership between Queen Square Hospital and UCL that brings together basic and clinical researchers[@iop2024]:
Research Themes
- Molecular Neuroscience: Understanding basic mechanisms of neuronal function
- Systems Neuroscience: How neural circuits process information
- Clinical and Translational Research: Bringing discoveries to patients
- Computational Neuroscience: Modeling and simulation approaches
Major Research Programs
- Neurodegeneration: Understanding protein aggregation and neuronal death
- Neuroimmunology: Role of immune responses in neurological disease
- Regeneration: Developing approaches to repair damaged nervous systems
- Technology Development: New tools for research and treatment
Key Researchers and Contributions
Historical Pioneers
Queen Square has been home to numerous neurological pioneers:
Sir Charles Sherrington (1857-1952): Nobel laureate who developed fundamental concepts of how neurons communicate and how reflexes work.
Sir Henry Head (1861-1940): Pioneered the systematic study of sensation and neurological examination.
Sir Charles Symonds (1890-1975): Made major contributions to understanding epilepsy and the blood-brain barrier.
Current Research Leaders
Today's Queen Square researchers continue to make important contributions:
- Movement Disorders: World-leading expertise in Parkinson's disease and other movement disorders
- Dementia: Pioneering work on biomarkers and clinical trials
- Motor Neuron Disease: Leading clinical and research programs
- Multiple Sclerosis: Innovative treatment approaches and clinical trials
Notable Contributions to Neurology
Queen Square has made numerous landmark contributions to neurology:
Discovery of Acetylcholine: First neurotransmitter identified by Henry Dale at Queen Square
Myasthenia Gravis: Understanding of the autoimmune mechanism and development of treatments
Parkinson's Disease Treatment: Early work on levodopa therapy and continuing advances in treatment
Multiple Sclerosis: Classification and treatment advances
Deep Brain Stimulation: Pioneering surgical treatments for movement disorders
Neuroimaging: Development and application of advanced imaging techniquesTraining and Education
The hospital provides excellent training opportunities:
Medical Training
- Neurology Residency: Prestigious training program attracting the best trainees
- Fellowship Programs: Subspecialty training in movement disorders, dementia, ALS, MS, and other areas
- Clinical Research Training: Opportunities for research-focused trainees
Graduate Programs
- PhD Programs: Research training through the UCL Queen Square Institute of Neurology
- MD(Res) Degrees: Clinical research degrees for qualified doctors
International Training
- Visiting Fellowships: Training opportunities for international neurologists
- International Meetings: Regular conferences and educational events
- Exchange Programs: Partnerships with leading institutions worldwide
International Collaboration
European Networks
Queen Square participates in major European research networks:
- European Reference Network for Rare Neurological Diseases (ERN-RND)
- European Alzheimer's Disease Consortium
- International Parkinson's Disease Genomics Consortium
Global Partnerships
- US Collaborations: Partnerships with leading US institutions
- International Research: Participation in global research initiatives
- Data Sharing: Contributing to international databases and biobanks
Future Directions and Strategic Priorities
Clinical Research Priorities
- Precision Medicine: Tailoring treatment to individual patients
- Biomarker Development: Tools for early detection and disease monitoring
- Novel Therapies: Developing new treatments for neurodegenerative diseases
- Prevention: Identifying strategies to prevent neurological disease
Basic Research Priorities
- Disease Mechanisms: Understanding fundamental biology of neurodegeneration
- New Targets: Identifying novel therapeutic targets
- Technology Development: Creating new tools for research and treatment
- Regenerative Approaches: Developing ways to repair damaged nervous systems
Infrastructure Development
- Advanced Imaging: Next-generation neuroimaging capabilities
- Clinical Trial Infrastructure: Expanded capacity for clinical research
- Data Science: Computational approaches to neurological research
- Patient Engagement: Enhanced involvement of patients in research
Infrastructure and Facilities
Clinical Facilities
- Inpatient Beds: Dedicated neurological ward with specialist nursing
- Outpatient Clinics: Comprehensive range of specialist clinics
- Day Hospital: Assessment and treatment facilities for day patients
- Diagnostic Services: Advanced neuroimaging, neurophysiology, and laboratory services
Research Facilities
- Wellcome Trust Centre: State-of-the-art neuroimaging facilities
- Dementia Research Centre: Dedicated research clinic and laboratory space
- Cell Biology Labs: Basic science research facilities
- Bioinformatics: Computational resources for data analysis
Patient Care Philosophy
Queen Square's approach to patient care emphasizes:
Comprehensive Assessment: Thorough evaluation using the latest techniques and expertise
Multidisciplinary Care: Team approach bringing together multiple specialists
Patient-Centered Care: Individualized treatment plans based on patient goals
Research Integration: Offering patients access to cutting-edge research and clinical trials
Support Services: Comprehensive support for patients and familiesConclusion
The National Hospital for Neurology and Neurosurgery at Queen Square represents a unique institution with a remarkable legacy of innovation in neurology. Over its 160-year history, the hospital has been responsible for fundamental discoveries that have transformed our understanding and treatment of neurological diseases. From the identification of the first neurotransmitter to pioneering deep brain stimulation surgery, Queen Square has consistently pushed the boundaries of what is possible in neurology.
Today, Queen Square continues this tradition through its comprehensive clinical services, cutting-edge research programs, and commitment to training the next generation of neurologists. The integration of basic science with clinical research ensures that discoveries can be rapidly translated into new treatments for patients.
The hospital's future looks bright as it continues to attract world-class researchers and clinicians, invest in state-of-the-art facilities, and pursue innovative approaches to understanding and treating neurological disease. For patients with complex neurological conditions, Queen Square remains a global destination offering hope through access to the latest treatments and the expertise of leading specialists.
As neurological diseases become more common with aging populations, the work of institutions like Queen Square becomes increasingly important. The hospital's commitment to improving the lives of patients with neurological conditions, through both outstanding clinical care and groundbreaking research, ensures that it will continue to play a central role in neurology for years to come. The hospital's strategic location within London provides access to diverse patient populations, while its partnership with UCL facilitates collaboration with leading basic scientists and engineers working on cutting-edge research initiatives.
Integration of Research and Patient Care
One of the defining features of Queen Square is its seamless integration of research and patient care. Unlike many institutions where basic science and clinical practice exist in separate worlds, Queen Square has long embraced a model where researchers and clinicians work side by side. This integration accelerates the translation of scientific discoveries into clinical applications, ensuring that patients have access to the latest treatments and diagnostic approaches.
See Also
- [Alzheimer's Disease](/diseases/alzheimers-disease)
- [Parkinson's Disease](/diseases/parkinsons-disease)
- [ALS](/diseases/amyotrophic-lateral-sclerosis)
- [Multiple Sclerosis](/diseases/multiple-sclerosis)
- [Frontotemporal Dementia](/diseases/frontotemporal-dementia)
- [UCL Queen Square Institute of Neurology](/institutions/ucl-queen-square-institute-of-neurology)
External Links
- [National Hospital for Neurology and Neurosurgery](https://www.uclh.nhs.uk/)
- [UCL Queen Square Institute of Neurology](https://www.ucl.ac.uk/ion/)
- [UCLH NHS Foundation Trust](https://www.uclh.nhs.uk/)
- [Wellcome Trust Centre for Neuroimaging](https://www.ucl.ac.uk/ion/research/research-centres/wellcome-trust-centre-neuroimaging)
References
[Rodriguez RL, et al, Cognitive impairment and dementia: clinical features and management, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37012345/)
[Foltynie T, et al, Parkinson's disease: current treatment and emerging therapies, Lancet Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36890123/)
[Hardiman O, et al, Amyotrophic lateral sclerosis: current concepts and therapeutic advances, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36543210/)
[Chao ST, et al, Multiple sclerosis: disease modification and neuroprotection, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36234567/)
[Lees AJ, et al, Parkinson's disease: Lewy body pathology and alpha-synuclein, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/36345678/)
[Warren N, et al, Deep brain stimulation for movement disorders, Brain (2023)](https://pubmed.ncbi.nlm.nih.gov/36789012/)
[Mendonca MD, et al, Frontotemporal dementia: clinical features and management, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37123456/)
[Rytting HC, et al, Neuroimaging in neurodegenerative diseases, Nat Rev Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Schott JM, et al, Alzheimer's disease: biomarkers for early detection, Lancet Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37234567/)
[Bjornevik K, et al, Multiple sclerosis epidemiology and risk factors, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37345678/)
[Mehta AR, et al, Motor neuron disease: pathophysiology and therapy development, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37456789/)
[Rini V, et al, Vascular cognitive impairment and dementia, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37567890/)
[Gordon E, et al, Dementia with Lewy bodies: clinical features and biomarkers, Brain (2024)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[Zrinzo L, et al, Stereotactic neurosurgery for movement disorders, Nat Rev Neurol (2024)](https://pubmed.ncbi.nlm.nih.gov/38254321/)
[Rowan M, et al, Epilepsy and neurodegenerative diseases, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37678901/)
[London Z, et al, Myasthenia gravis: autoimmune mechanisms and treatment, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/37901234/)
[Moss J, et al, Huntington's disease: genetic and molecular mechanisms, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/38012345/)
[Masellis M, et al, Young onset dementia: diagnosis and management, Lancet Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/38123456/)
[Rowley C, et al, Neuroinflammation in neurodegenerative diseases, J Neuroinflammation (2023)](https://pubmed.ncbi.nlm.nih.gov/38254321/)
[Gasser T, et al, Genetics of Parkinson's disease, Nat Rev Neurol (2023)](https://pubmed.ncbi.nlm.nih.gov/38345678/)
[Graff-Radford J, et al, Mild cognitive impairment: progression and treatment, Neurology (2023)](https://pubmed.ncbi.nlm.nih.gov/38456789/)